Nobiletin may exert therapeutic effects in type 2 diabetes by downregulating ACSL4, with the study confirming that administration of the drug at a dose of 5 mg/kg yielded a beneficial effect in the rat model [208]. Here, ACSL4 is linked to type 2 diabetes mellitus.